glucagon in retatrutide Retatrutide: How the Triple Agonist Compares to Tirzepatide Retatrutide (LY3437943) | MyBioSource

"Fewer than 1 in 10 people who could benefit from a GLP-1 are taking one." "People living with obesity need treatment options that meet them where they are and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," she said in the same press release

They found that 9% had an outright deficiency and 16% exhibited a near deficiency. Many of these individuals were suffering from neurological symptoms (4)

How GLP-1 Medications Change Your Body in the First 30 Days Your first injection sets off a cascade of changes

Patients should work with their healthcare team to ensure their reduced food intake still meets nutritional requirements

You have 60 days from the date of this letter to appeal the coverage denial